19 May 2013
Keywords: roche, avastin, fails, show, overall, survival, bevacizumab
Article | 28 April 2008
Roche's Avastin (bevacizumab) failed to show an overall survival benefit in a European lung cancer trial. The Swiss drug major's $4.1
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 April 2008
14 April 2008
17 May 2013
© 2013 thepharmaletter.com